Venetoclax Study for Kids with Relapsed AML

This study tests if adding venetoclax to a chemotherapy mix helps kids and young adults with a type of cancer called acute myeloid leukemia (AML) that has returned. Venetoclax helps kill cancer cells by stopping a protein that protects them. Participants will get two 42-day treatment cycles with venetoclax and chemotherapy before a possible stem cell transplant. If the transplant isn't possible, they might continue with venetoclax alone.

• Study Length: Up to 24 cycles of maintenance therapy.
• Participants: Children and young adults aged 29 days to 21 years with specific AML relapse conditions.
• Risks: Potential side effects from venetoclax and chemotherapy; must be free from certain health conditions to join.

To join, participants should not have Down syndrome or specific other health issues, and they need to have some prior medical tests and conditions checked. They must also stop certain medicines and foods before starting. This study requires a consent form signed by the participant and a guardian.